Low-Molecular-Weight Dextran in Treatment of Bone-Pain Crises in Sickle-Cell Disease

Barnes, P.M.; Hendrickse, R. G.; Watson-Williams, E.

doi:10.1016/s0140-6736(65)92284-1

Cited by 24 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dr E J Watson-Williams (Department ofClinical Hematology, The University and Royal Infirmary, Manchester) Preliminary clinical studies suggested that low molecular weight dextran might be valuable in the treatment of patients with bone-pain crises in sickle cell disease. A controlled clinical trial showed, however, that it was of no more benefit than was intravenous infusion of 5 % dextrose in water (Barnes et al 1965). Rapid intravenous infusion of any isotonic solution will materially reduce pain in about 50 % of patients.…”

Section: Resultsmentioning

confidence: 99%

The Management of Anæsthesia in Sickle Cell States [Abridged]

Ball

1967

Proceedings of the Royal Society of Medicine

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

The Management of Anæsthesia in Sickle Cell States [Abridged]

Ball

1967

Proceedings of the Royal Society of Medicine

View full text Add to dashboard Cite

“…Sodium bicarbonate Schwartz and McElfresh (1964) Dextran Barnes, Hendrickse, and Watson-Williams (1965…”

Section: Agent Trialmentioning

confidence: 99%

Management of sickle-cell disease

Stuart¹

1974

J Clin Pathol

View full text Add to dashboard Cite

The two most controversial aspects of the management of sickle-cell disease are first, the treatment of the painful, vasoocclusive crisis and second, the value of community screening programmes. The controversy over treatment of the painful crisis has followed the promotion of urea as a clinically effective anti-sickling agent (Nalbandian, Shultz, Lusher, Anderson, and Henry, 1971; McCurdy and Mahmood, 1971) against a long background history of failure to evaluate potential anti-sickling agents by controlled clinical trial. The controversy over community screening has been exacerbated by the passage, in 1972, of the United States Congress National Sickle Cell Anemia Control Act; as a result, 10 states, containing more than 40% of the black population of the USA, have introduced laws requiring mandatory, rather than voluntary, screening for sickle-cell haemoglobin (Rutkow and Lipton, 1974). Both of these aspects are now relevant to the care of immigrant patients in the United Kingdom and to the establishment in this country of cooperative clinical trials and community screening programmes. Management of the Sickle-cell Crisis TYPES OF CRISIS The term 'crisis' in sickle-cell disease may be used to describe the vasoocclusive episodes of tissue infarction (painful crisis) or episodes of sudden anaemia resulting from marrow hypoplasia, an exacerbation of haemolysis, or splenic sequestration (haematological crisis). In a paediatric population receiving folic acid supplements we have found that hyperhaemolytic crises and episodes of erythroid hypoplasia are relatively common causes of a profound fall in haemoglobin. These haemolytic episodes may be precipitated by a viral infection associated with cold antibody formation (Cotter, Walker, Bird, Mann, and Stuart, 1974). There is, however, insufficient information concerning the frequency and cause of these hypoplastic, haemolytic, and sequestration crises, and cooperative studies involving investigation and treatment are required. This is particularly important in obstet-26 rical practice because of the high maternal and perinatal mortality (Fort, Morrison, Berreras, Diggs, and Fish, 1971).

show abstract

“…Preliminary clinical studies suggested that low molecular weight dextran might be valuable in the treatment of patients with bone-pain crises in sickle cell disease. A controlled clinical trial showed, however, that it was of no more benefit than was intravenous infusion of 5 % dextrose in water (Barnes et al 1965). Rapid intravenous infusion of any isotonic solution will materially reduce pain in about 50 % of patients.…”

mentioning

confidence: 99%

The Management of Anæsthesia in Sickle Cell States [Abridged]

Watson-Williams

1967

Proceedings of the Royal Society of Medicine

View full text Add to dashboard Cite

Low-Molecular-Weight Dextran in Treatment of Bone-Pain Crises in Sickle-Cell Disease

Cited by 24 publications

References 5 publications

The Management of Anæsthesia in Sickle Cell States [Abridged]

The Management of Anæsthesia in Sickle Cell States [Abridged]

Management of sickle-cell disease

The Management of Anæsthesia in Sickle Cell States [Abridged]

Contact Info

Product

Resources

About